gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Douglas J. Schwartzentruber, David H. Lawson, Jon Richards, Robert M. Conry, Donald M. Miller, Jonathan Treisman, Fawaz Gailani, Lee B. Riley, Kevin C. Conlon, Barbara A. Pockaj, Kari Kendra, Richard L. White, René González, Timothy M. Kuzel, Brendan D. Curti, Phillip D. Leming, Eric D. Whitman, Jai Balkissoon, Douglas S. Reintgen, Howard L. Kaufman, Francesco M. Marincola, Maria J. Merino, Steven A. Rosenberg, Peter L. Choyke, Don Vena, Patrick Hwu

New England Journal of Medicine, 2011

Indiana University Health, Goshen Health, Cancer Institute (WIA), Emory University, Oncology Specialists, James Graham Brown Foundation, Aurora St. Luke's Medical Center, Kaiser Permanente Riverside Medical Center, St. Vincent's Medical Center, St. Luke's Hospital, Mayo Clinic Hospital, The Ohio State University, Carolinas Medical Center, University of Colorado Denver, Providence Portland Medical Center, Christ Hospital, Atlantic Health System, Alta Bates Summit Medical Center, University of South Florida, Rush University Medical Center, National Institutes of Health, Emmes (United States), The University of Texas MD Anderson Cancer Center

Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

882

Citations

View on Google Scholar

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

Abstract

Journal Details

Join JournalsHub

Welcome Back